title: Atypical antipsychotics: new drugs, new challenges.
abstract: Compared with the first-generation, or "typical" antipsychotic drugs, second-generation or atypical antipsychotics cause fewer extrapyramidal (motor) problems, but they pose new challenges, as they often contribute to metabolic disturbances such as weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus. Patients taking atypical antipsychotics should be monitored for glycemic and cardiovascular risk factors and should receive treatment for such problems as they arise.
authors: Department of Psychiatry and Psychology, Cleveland Clinic Foundation, OH 44195, USA.
authors: Manu
authors: M
authors: Mathews
authors: David J
authors: DJ
authors: Muzina
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced; D006801:Humans; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D018967:Risperidone / Q000627:therapeutic use; D015430:Weight Gain
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine